Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108955 | 1.00 | HTR2C (0.45) | HTR2CHTR2AHTR2BHCRTR2TSHR | |
| SCHEMBL317993 | 0.81 | LMNA (0.43) | MEN1KMT2A | |
| SCHEMBL10109114 | 0.81 | LMNA (0.43) | MEN1KMT2A | |
| SCHEMBL317304 | 0.77 | HTR2C (0.51) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL10108951 | 0.77 | HTR2C (0.51) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL10674865 | 0.77 | HTR2C (0.48) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL10108965 | 0.77 | HTR2C (0.48) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL316665 | 0.77 | HTR2C (0.48) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL10710538 | 0.76 | FABP7 (0.47) | HTR2CHTR2AHTR2BDRD2FABP7 | |
| SCHEMBL10108970 | 0.76 | FABP7 (0.47) | HTR2CHTR2AHTR2BDRD2FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1853578-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006088716-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | HTR2C 356/4885HTR2A 404/4885HTR2B 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.